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ABSTRACT 
Low blood levels of B vitamins have been implicated in age-associated cognitive 
impairment. The present study investigated the association between genetic variation 
in folate metabolism and age-related cognitive decline in the ninth decade of life. 
Both the 677C>T (rs1801133) polymorphism and the scarcely-studied 1298A>C 
(rs1801131) polymorphism of the MTHFR gene were assessed in relation to cognitive 
change over 8 years in older community-dwelling individuals. MTHFR genotype was 
determined in 476 participants of the Lothian Birth Cohort 1921, whose intelligence 
was measured in childhood in the Scottish Mental Survey of 1932. Cognitive 
performance on the domains of verbal memory, abstract reasoning, and verbal fluency 
was assessed at mean age 79 (n = 476), and again at mean ages of 83 (n = 275) and 87 
(n = 180). Using linear mixed models, the MTHFR 677C>T and 1298A>C variants 
were not associated with the rate of cognitive change between 79 and 87 years, 
neither in the total sample, nor in a subsample of individuals with erythrocyte folate 
levels below the median. APOE E4 allele carrier status did not interact with MTHFR 
genotype in affecting change in cognitive performance over 8 years. A joint analysis 
investigating the combined effect of both polymorphisms did not reveal any 
significant results. In conclusion, MTHFR 677C>T and 1298A>C polymorphisms 
were not associated with individual change in cognitive functioning in the ninth 
decade of life. Although polymorphisms in the MTHFR gene may cause disturbances 
in folate metabolism, they do not appear to be accompanied by changes in cognitive 
functioning in old age.  
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INTRODUCTION 
Low blood levels of B vitamins, such as folate and vitamin B12, have been 
implicated in age-associated cognitive impairment (Clarke et al., 2007, Kado et al., 
2005). A low folate status may result from poor dietary intake, or from genetic 
disturbances in folate metabolism. For example, the common 677C>T (rs1801133) 
and 1298A>C (rs1801131) polymorphisms of the 5,10-methylenetetrahydrofolate 
reductase (MTHFR) gene may mimic dietary folate deficiency by reducing folate 
metabolism (Frosst et al., 1995, Weisberg et al., 1998). The non-synonymous 
MTHFR 677C>T and 1298A>C polymorphisms are associated with decreased 
MTHFR activity (Frosst et al., 1995, Weisberg et al., 1998), resulting in reduced 
availability of 5-methyltetrahydrofolate for the conversion of homocysteine into 
methionine. Both polymorphisms have been found to increase homocysteine levels, 
although the effects of the 1298A>C polymorphism are somewhat less pronounced 
than those associated with the 677C>T polymorphism (Friedman et al., 1999).  
In addition, by reducing the availability of methyl donors, MTHFR 677C>T 
and 1298A>C polymorphisms may impair DNA methylation processes (Castro et al., 
2004, Friso et al., 2002), which play a key role in regulating gene expression. As both 
DNA hypomethylation and elevated homocysteine levels have been related to deficits 
in cognitive functioning (Levenson & Sweatt, 2005, Mattson & Shea, 2003, Zhao et 
al., 2003), we hypothesized that the MTHFR 677C>T and 1298A>C polymorphisms 
might confer increased susceptibility to cognitive impairment and age-related 
cognitive decline.  
To date, a number of studies have examined the associations between the 
MTHFR 677C>T polymorphism and cognitive functioning in older individuals 
(Almeida et al., 2005, Bathum et al., 2007, Durga et al., 2006, Elkins et al., 2007, 
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Gussekloo et al., 1999, Visscher et al., 2003), albeit with mixed results. The possible 
relationship between the 1298A>C polymorphism and cognitive performance, 
however, has scarcely been investigated (De Lau et al., 2008).  
It should be noted that most of the previous studies were cross-sectional. Few 
studies have addressed the relationship between MTHFR genotype and longitudinal 
change in cognitive functioning in the ageing population (Bathum et al., 2007, Elkins 
et al., 2007). Whereas the MTHFR 677TT genotype was associated with greater 
annual cognitive decline in a large population-based sample of older women (Elkins 
et al., 2007), no such associations were found in community-dwelling nonagenarians 
whose cognitive performance was assessed over 5 years (Bathum et al., 2007).  
In some of the above-mentioned studies, possible associations between 
MTHFR genotype and cognitive performance might have been obscured by not taking 
into account individual variation in folate status, because phenotypic expression of the 
MTHFR 677TT genotype is most pronounced when folate status is low (Girelli et al., 
1998).  
In addition, few of the earlier studies controlled for prior cognitive ability, 
which may confound the relationship between MTHFR polymorphisms and age-
related cognitive change, because childhood mental ability accounts for about half of 
the variance associated with cognitive ability in adulthood (Deary et al., 2004).  
Furthermore, APOE E4 carrier status has been suggested to interact with a low 
B vitamin status to increase individual vulnerability to cognitive impairment (Bunce 
et al., 2004, Shea et al., 2004). However, the putative interactions between MTHFR 
genotype and APOE E4 carrier status have rarely been studied. 
The objective of the present study was, therefore, to examine the longitudinal 
associations between the MTHFR 677C>T and 1298A>C polymorphisms and key 
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domains of cognitive functioning in the healthy ageing population, while taking into 
account folate status, prior cognitive ability, and APOE E4 allele carrier status. We 
assessed cognitive performance three times between mean ages of 79 and 87 in a 
sample of older individuals whose mental ability was measured in childhood: the 
Lothian Birth Cohort 1921 (Deary et al., 2004). By using a cohort with very little age 
variation, any problems associated with heterogeneity of MTHFR’s effect on 
cognitive performance at different ages were excluded. 
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MATERIALS AND METHODS 
Study population 
The study population was the Lothian Birth Cohort 1921. This cohort 
consisted of 550 surviving participants of the Scottish Mental Survey 1932, which 
tested cognitive ability in almost all children born in 1921 and attending school in 
Scotland in June 1932 (Scottish Council for Research in Education, 1933). 
Participants living in Edinburgh and the surrounding areas were recruited for medical 
and cognitive retesting via general practitioner’s patient lists and advertisements in 
the media, as described in detail elsewhere (Deary et al., 2009, Deary et al., 2004).  
All participants who had completed the initial reassessments at mean age 79 
years (old age baseline), excluding those who had withdrawn or were known to have 
died, were invited to participate in the follow-up measurements at mean age 83. In 
addition, all participants who had completed the assessments at mean age 83, 
excluding those who had withdrawn or were known to have died, were invited to take 
part in the follow-up measurements at mean age 87. Of the 454 participants invited to 
take part at age 83, 335 agreed to participate, and 321 were tested. At mean age 87, 
268 participants were invited, and 207 were tested (Gow et al., in press). Reasons for 
not attending included withdrawal (n = 16 at age 83; n = 4 at age 87), inability or 
refusal to participate (n = 80 at age 83; n = 42 at age 87), having moved away (n = 13 
at age 83; n = 4 at age 87), exclusion due to dementia or memory problems (n = 3 at 
age 87), and death (n = 10 at age 83; n = 8 at age 87) (Gow et al., 2008, Starr et al., 
2010). Of the total sample of 550 individuals, 229 had died during the course of the 
study. At baseline, all participants lived independently in the community and most 
were in good general health.  
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Baseline data on cognitive functioning were lacking for two individuals. At 
baseline, five participants reported a history of dementia-related illness, and nine 
individuals scored < 24 on the Mini-Mental State Examination (MMSE) (Folstein et 
al., 1975), which may suggest possible dementia. These individuals were excluded 
from statistical analysis, along with 27 participants who maintained contact with the 
study and developed symptoms of dementia during follow-up. MTHFR genotyping 
was successful for all but 31 of the 507 participants with valid cognitive data at 
baseline. The resulting study sample consisted of 476 individuals (192 men, 284 
women) at baseline, 275 individuals (118 men, 157 women) at mean age 83, and 180 
individuals (77 men, 103 women) at mean age 87.  
The Multi-Centre Research Ethics Committee for Scotland and the Lothian 
Research Ethics Committee approved the study. All participants gave written, 
informed consent. 
 
Cognitive tests 
In the Scottish Mental Survey of 1932, a version of the Moray House Test No. 
12 (MHT) was administered as a measure of general cognitive ability at age 11 years 
(Scottish Council for Research in Education, 1933). Although it is primarily focused 
on verbal reasoning, this test also assesses numerical, spatial, and general reasoning. 
The MHT, consisting of 71 numbered items, 75 items in total, is to be completed 
within 45 min, and has a maximum test score of 76. Raw MHT test scores were 
corrected for age in days at the time of testing and converted to IQ-type scores (mean 
= 100, SD = 15). 
At each wave of testing in old age, a battery of cognitive tests was 
administered to assess the important cognitive domains of verbal fluency, verbal 
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memory, and abstract reasoning. The Verbal Fluency Test (Lezak, 1995) provides a 
measure of executive functioning. Participants are required to name as many words as 
possible beginning with the letter C in 1 min. This process is repeated for the letters F 
and L. The overall test score is the total number of correct words named, excluding 
proper names, numbers, and repeated words. Verbal declarative memory was assessed 
by means of the Logical Memory subtest from the Wechsler Memory Scale–Revised 
(Wechsler, 1987). Two short stories, each containing twenty-five memory items, are 
read aloud. Immediately after each story, the participants recall as much of the story 
as possible (‘immediate recall’). After a delay of about 25 min, the participants are 
again asked to recall as much as they can (‘delayed recall’). The total score is the sum 
of the two immediate and two delayed recall scores. Maximum possible overall test 
score is 100. Raven’s Standard Progressive Matrices (Raven et al., 1977) was used to 
measure abstract reasoning. The test consists of sixty items, each presenting a pattern 
that needs to be completed. Participants complete as many items as possible in 20 
min. The outcome measure is the total number of correctly completed items. 
 
Genotyping 
MTHFR genotype was determined at as described previously (Houlihan et al., 
2010). In short, for 542 of the 550 participants in the LBC1921, genomic DNA was 
isolated from whole blood by standard procedure at Medical Research Council 
Technology, Western General Hospital, Edinburgh. Sixteen samples failed quality 
control preceding the genotyping procedure. The remaining 526 samples were 
genotyped by the Wellcome Trust Clinical Research Facility (WTCRF) Genetics Core 
with the Illumina Human610-Quadv1 chip. These samples were then subjected to 
quality-control procedures. All individuals were checked for disagreement between 
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genetic and reported gender (n = 1). Relatedness between participants was 
investigated and, for any related pair of individuals, one was removed (n = 1). 
Samples with a call rate ≤ 0.95 (n = 5), and those showing evidence of non-Caucasian 
descent by multidimensional scaling, were also removed (n = 2). The MTHFR 
677C>T and 1298A>C polymorphisms met the following conditions: call rate ≥ 0.98, 
minor allele frequency ≥ 0.01, and Hardy-Weinberg equilibrium test with p ≥ 0.001. 
In total, 517 samples remained. 
APOE genotype was determined by PCR amplification of a 227-bp fragment 
of the APOE gene containing two polymorphic sites that account for the three alleles, 
E2, E3, and E4 (Wenham et al., 1991), followed by restriction digest with CfoI and 
electrophoresis in 4% NuSieve gel. 
 
Blood measurements 
Venous blood samples were collected at baseline and at mean age 87. The 
blood samples were processed and stored at -80°C until analysed. Erythrocyte folate 
concentrations were measured by immunoassay (Advia Centaur Immuno Assay 
System, Siemens Healthcare Diagnostics, Deerfield, IL). Data on erythrocyte folate 
status were available for 399 individuals at baseline, and 128 individuals at mean age 
87. 
 
Lifestyle and health-related variables 
 Body mass index (BMI, kg/m2), smoking status (current smoking, yes/no), and 
alcohol consumption (standard units per week) were recorded at baseline. Physical 
activity, recorded as the frequency (days/month) of sport or physical exercise lasting 
at least 20 min at a time, was assessed at baseline. As these lifestyle and health-related 
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variables may confound the associations between folate metabolism and cognitive 
performance (Feng et al., 2006, Kado et al., 2005, Koike et al., 2008), they were 
included as covariates in the statistical models to reduce residual variation in the 
outcome measures. 
 
Statistical analysis 
Normality of data distributions was ascertained by means of normal Q-Q 
plots. The MTHFR genotypes were defined as rare variant (677TT or 1298CC) or 
common variant (677CC/677CT or 1298AA/1298AC). A recessive genetic model 
was used to test the associations between MTHFR genotype and cognitive 
performance, as previous studies have indicated that plasma homocysteine 
concentrations were significantly increased in persons with the MTHFR 677TT rare 
variant, but not in persons with the 677CC and 677CT common variants (Frosst et al., 
1995, Weisberg et al., 1998).  
The cross-sectional and longitudinal associations between the MTHFR 
polymorphisms and cognitive functioning were assessed by means of linear mixed 
models (Verbeke & Molenberghs, 2000). This analysis method takes into account the 
intraindividual correlation between repeated measurements and allows the inclusion 
of participants with incomplete data at follow-up. Changes over time within 
individuals, i.e. the longitudinal effect, are distinguished from differences among 
individuals at baseline, i.e. the cross-sectional effect. Akaike’s Information Criterion 
indicated that a Toeplitz covariance structure best fitted the data. Separate models 
were fitted for the MTHFR 677C>T and 1298A>C genotypes in relation to each of the 
dependent cognitive variables, i.e. Verbal Fluency, Logical Memory, and Raven’s 
Matrices. Time (measured in years since baseline, which is acceptable because there 
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is very little age variation among the participants within each wave) was included to 
estimate the change in cognitive performance between 79 and 87 years. The main 
effect of MTHFR genotype represents the cross-sectional association between 
MTHFR genotype and cognitive performance at baseline. The longitudinal effect of 
MTHFR genotype was estimated by the two-way interaction between time and 
MTHFR genotype, which represents the rate of change in cognitive performance over 
8 years as a function of MTHFR genotype. The statistical models were adjusted for a 
number of covariates in three consecutive steps. In Model 1, the analyses were 
corrected for the demographic variables age (in days), age2 (to test for non-linear 
effects of age), and sex (Model 1). Age was centered around the mean to reduce the 
correlation between the terms for age and age2. In Model 2, the analyses were 
additionally adjusted for age 11 MHT IQ to reduce the confounding effect of prior 
cognitive ability on age-related change in cognitive performance. In Model 3, the 
lifestyle and health-related variables BMI, smoking status, alcohol consumption, and 
physical activity were entered (Model 3).  
The analyses were repeated in a subsample of individuals with erythrocyte 
folate concentrations below the median, i.e. 314 µg/L (n = 203), as low folate 
concentrations may increase the phenotypic expression of the genotypes studied 
(Girelli et al., 1998). In addition, the analyses were stratified by APOE E4 carrier 
status (defined as E4+ or E4−, depending on the presence or absence of at least one 
E4 allele) to investigate whether the cross-sectional and longitudinal associations 
between the MTHFR polymorphisms and cognitive functioning differed between 
carriers and non-carriers of the APOE E4 allele.  
In secondary analyses, linear mixed models, corrected for demographic and 
health-related variables, were performed for both the MTHFR 677C>T and 1298A>C 
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polymorphisms to examine the possibility of a linear trend in cognitive performance 
associated with the presence of zero, one, or two variant alleles. In addition, as the 
MTHFR 677C>T and 1298A>C polymorphisms are in linkage disequilibrium 
(Stegmann et al., 1999), linear mixed models, corrected for demographic and health-
related variables, were performed to investigate the combined effect of these 
polymorphisms on cognitive performance. To this end, the combined MTHFR 
677C>T/1298A>C genotypes were classified as 677CC/1298AA, 677CC/1298AC, 
677CC/1298CC, 677CT/1298AA, 677CT/1298AC, or 677TT/1298AA. 
Statistical differences were considered significant at p-values < 0.05. All 
analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL). 
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RESULTS 
Descriptives 
Table 1 shows the baseline characteristics of the study sample. Chi-square 
tests indicated that the MTHFR 677C>T and 1298A>C genotypes were in Hardy-
Weinberg equilibrium (p = 0.797 and p = 0.982, respectively). The allele frequencies 
were as follows: 677C = 0.65, 677T = 0.35, 1298A = 0.71, and 1298C = 0.29. These 
frequencies are comparable to those reported in other population-based samples 
(Elkins et al., 2007, Weisberg et al., 1998). Distribution of the combined 
677C>T/1298A>C genotypes was as follows: 677CC/1298AA, n = 67 (14.1%); 
677CC/1298AC, n = 97 (20.4%); 677CC/1298CC, n = 38 (8.0%); 677CT/1298AA, n 
= 112 (23.5%); 677CT/1298AC, n = 99 (20.8%); and 677TT/1298AA, n = 63 
(13.2%). Individuals with the rare variant of one polymorphism (677TT or 1298CC) 
were always homozygous wildtype for the other polymorphism (1298AA or 677CC, 
respectively); none of the participants had more than two variant alleles. Erythrocyte 
folate concentrations did not differ significantly between individuals homozygous for 
the rare 677T or 1298C polymorphism and individuals carrying the common 
polymorphisms (p = 0.079 and p = 0.440, respectively). Independent samples t tests 
and Chi-square tests indicated that the covariates did not differ between individuals 
with the 677TT or 1298CC genotype and the other participants, except for age at 
baseline, which was higher in individuals with the 1298CC genotype as compared 
with the rest of the sample (mean ± SD = 79.3 ± 0.6 and 79.0 ± 0.6, respectively; p = 
0.004). Participants homozygous for the 677C>T or 1298A>C rare variant did not 
differ from the other participants in terms of cognitive test performance at baseline or 
at follow-up (Tables 2 and 3). 
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Logistic regression analysis revealed that dropout was not associated with 
MTHFR 677C>T or 1298A>C genotype (p = 0.544 and p = 0.570, respectively). 
However, lower cognitive scores at baseline significantly predicted dropout at follow-
up (p < 0.01 for each of the three cognitive measures). Chi-square tests indicated that 
participants who were lost to follow-up did not differ from the remaining participants 
in terms of demographic or health-related characteristics, except for smoking, which 
significantly increased the likelihood of dropping out (p = 0.023).  
  
Associations between MTHFR polymorphisms and cognitive decline 
Tables 4 and 5 show the results of the linear mixed model analyses. Cognitive 
performance on the domains of verbal fluency and abstract reasoning declined by 
2.0% and 13.3%, respectively, between 79 and 87 years, while Logical Memory 
scores did not show a significant decline over the 8-year follow-up period. For verbal 
fluency, the effect of time was statistically significant in the models with MTHFR 
677C>T genotype as the independent variable (Table 4), but not in the models with 
MTHFR 1298A>C genotype as the independent variable (Table 5). This discrepancy 
can be explained by the fact that part of the variance associated with time was 
accounted for by the interaction term for time × genotype; the main effect of time was 
similar in both models when no interaction term was included, i.e. parameter estimate 
(95% CI) = -0.20 (-0.38, -0.03), p = 0.025 in the fully adjusted models.  
The MTHFR 677C>T and 1298A>C polymorphisms were not significantly 
associated with individual change in cognitive performance between 79 and 87 years 
on any of the domains measured. Stratifying the analyses by APOE E4 carrier status 
did not yield any significant results, indicating that APOE E4 allele did not modify the 
putative longitudinal associations between MTHFR genotype and cognitive 
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performance. Performing separate analyses for individuals with a low folate status did 
not reveal any associations between MTHFR polymorphisms and individual variation 
in the rate of cognitive change. Post-hoc analyses using linear mixed models with 
erythrocyte folate concentration as the independent variable revealed that folate status 
was not directly associated with individual change in cognitive performance between 
79 and 87 years.  
Linear mixed models investigating a linear trend in cognitive performance 
associated with the number of variant alleles did not reveal any significant results 
(data not shown), implying that the MTHFR 677C>T or 1298A>C polymorphisms did 
not show a dose-effect relationship with individual change in cognitive performance 
between mean ages of 79 and 87 years. When the combined effect of both 
polymorphisms was examined, no significant associations were identified (Table 6), 
indicating that the two polymorphisms did not interact in affecting age-related 
cognitive decline over 8 years. 
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DISCUSSION 
We showed that the MTHFR 677C>T and 1298A>C polymorphisms were not 
associated with individual change in cognitive performance on the domains of verbal 
fluency, verbal memory, and abstract reasoning between 79 and 87 years in older 
community-dwelling individuals. The present results suggest that altered folate 
metabolism due to reduced MTHFR activity does not influence cognitive 
performance or age-related cognitive decline in the ninth decade in the healthy ageing 
population.  
Our findings are in line with earlier studies reporting the lack of a relationship 
between MTHFR genotype and cognitive performance in older adults (Almeida et al., 
2005, Bathum et al., 2007, De Lau et al., 2008, Gussekloo et al., 1999, Visscher et 
al., 2003). However, Elkins et al. (2007) found that the MTHFR 677TT genotype was 
related to decreased information processing speed and executive functioning, as well 
as a small excess annual decline in global cognitive functioning in women aged 65 
years or older. In contrast, Durga and colleagues (2006) reported a positive cross-
sectional association between the 677TT genotype and sensorimotor speed in 
community-dwelling individuals aged 50 to 70 years.  
An important difference between the two above-mentioned studies and our 
study is the age range of the study samples, as the participants in the studies by Elkins 
et al. and Durga et al. were considerably younger than those included in the present 
study. Interestingly, it has been found that the effect of the MTHFR 677C>T 
polymorphism on homocysteine levels decreases with advancing age (Husemoen et 
al., 2003), implying that phenotypic expression of the 677TT genotype is weaker in 
older adults as compared with younger individuals. It might be hypothesized that the 
relationship between MTHFR genotype and cognitive performance may be more 
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prominent in younger populations, thereby leading to contrasting results when 
different age groups are compared. The interaction between MTHFR genotype and 
age seems to offer a reasonable explanation for the lack of a significant relationship 
between MTHFR polymorphisms and cognitive performance in the present study. In 
this respect, it is worth noting that most of the other studies reporting null findings on 
the relationship between MTHFR genotype and cognitive performance were also 
performed in study populations with a higher mean age than the samples used by 
Elkins et al. and Durga et al. (Almeida et al., 2005, Bathum et al., 2007, Gussekloo et 
al., 1999). 
Although phenotypic expression of the MTHFR 677TT genotype may 
decrease with advancing age, it may increase in the presence of a low folate status 
(Girelli et al., 1998). Therefore, we performed secondary analyses to determine 
whether MTHFR genotype was associated with cognitive performance in individuals 
with erythrocyte folate concentrations below the median. However, no significant 
associations were identified, which might have been related to the small number of 
participants with erythrocyte folate levels indicative of folate deficiency, i.e. below 
140 µg/L (n = 14).  
The present findings might imply that the MTHFR 677C>T and 1298A>C 
polymorphisms do not influence homocysteine levels or DNA methylation capacity to 
such an extent that cognitive performance is affected in the ninth decade. On the other 
hand, it might also be argued that these polymorphisms may simultaneously exert 
detrimental as well as beneficial effects, thereby causing no detectable changes in 
cognitive performance. For example, the MTHFR 677C>T polymorphism may have a 
negative impact on cognitive functioning by elevating homocysteine concentrations 
(Frosst et al., 1995) and impairing DNA methylation (Castro et al., 2004, Friso et al., 
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2002), but it might also exert positive effects by increasing the availability of 5,10-
methylenetetrahydrofolate for DNA synthesis (Skibola et al., 1999).  
The present results did not offer support for the hypothesis that APOE E4 
allele carrier status, which has been shown to increase the risk of cognitive 
impairment in older individuals (Caselli et al., 2009, Deary et al., 2002), might 
modify the putative associations between MTHFR genotype and cognitive 
performance. Our findings are in concordance with previous research, indicating that 
APOE E4 carrier status and disturbances in folate metabolism might represent two 
distinct routes to cognitive impairment (Gottfries et al., 2001). In a similar vein, 
Religa and colleagues (2003) reported that the association between APOE E4 carrier 
status and Alzheimer’s disease was unrelated to homocysteine levels, folate status, 
and MTHFR genotype. Furthermore, a case-control study by Brunelli et al. (2001) 
showed that MTHFR genotype was not associated with Alzheimer’s disease and did 
not interact with APOE E4 allele carrier status in mediating Alzheimer’s disease risk.  
Previously, we found that folate status was positively correlated with cognitive 
performance in healthy ageing individuals (Duthie et al., 2002, Starr et al., 2005). 
However, we did not find any evidence for a cross-sectional relationship between the 
MTHFR 677C>T polymorphism on the one hand and cognitive performance in old 
age or lifetime cognitive change on the other (Visscher et al., 2003). The present 
study further extends these observations by showing that neither the 677C>T nor the 
1298A>C polymorphism were related to individual variation in the rate of cognitive 
decline between 79 and 87 years.  
A common limitation of longitudinal studies is selective dropout. Statistical 
testing indicated that dropout was not related to MTHFR genotype in the present 
study. This finding was further supported by the fact that the MTHFR allele 
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frequencies in our study were comparable to those reported for younger populations 
(Friedman et al., 1999, Frosst et al., 1995, Weisberg et al., 1998). However, dropout 
was significantly associated with a lower level of cognitive performance at baseline. 
The use of a statistical method that allows for the inclusion of participants with 
missing data at follow-up enabled us to compensate, at least in part, for this selection 
bias.  
Another potential limitation of longitudinal studies is the repeated 
administration of cognitive tests, which may introduce learning effects. Learning 
effects on cognitive tests might be considered a disadvantage, as they may obscure 
age-related cognitive decline. In contrast to verbal fluency and abstract reasoning, 
which showed a gradual decline over 8 years of follow-up, verbal memory 
performance did not show a significant decline between 79 and 87 years in our study. 
This may be due to the effects of procedural learning. However, it is unlikely that 
learning effects on the Logical Memory test might have contributed to the lack of 
significant results in the present study, as longitudinal variability in cognitive 
performance is generally well preserved, thereby allowing for the detection of 
individual differences in the rate of age-associated cognitive change. 
The present study was characterized by substantial dropout (62%), due to the 
old age of the study participants. Although we used a the statistical method that 
allowed for the inclusion of individuals with missing data at follow-up, thereby 
preventing a large decrease in statistical power, we cannot rule out completely that 
our study might not have been able to detect very modest associations between 
MTHFR genotype and individual change in cognitive performance over 8 years. 
The strengths of our study were its longitudinal design, the use of sensitive, 
domain-specific cognitive tests, the narrow chronological age range of the sample, 
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and the adjustment for a number of potential confounders. In addition, not only did 
we investigate the relationship between cognitive performance and the common 
MTHFR 677C>T polymorphism, we also assessed the rarely-studied MTHFR 
1298A>C polymorphism. Furthermore, correcting the analyses for childhood 
intelligence enabled us to examine individual variation in the rate of cognitive change 
in old age, whilst eliminating the confounding influence of the stable trait of general 
mental ability (Deary et al., 2004).  
We conclude that the MTHFR 677C>T and 1298A>C polymorphisms are not 
associated with individual change in cognitive functioning in the ninth decade of the 
lifecourse. Although polymorphisms in the MTHFR gene may cause disturbances in 
folate metabolism, they do not appear to be accompanied by changes on the level of 
cognitive functioning in later life. Future studies are necessary to further investigate 
the extent to which genetic and environmental factors underlying individual 
differences in folate metabolism may be involved in age-related cognitive decline. 
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TABLE 1 Participant characteristics at baseline 
 Total sample 
n 476 
Age (years) 79.0 ± 0.6 
Female 284 (59.7%) 
Age 11 IQa 100.9 ± 14.4 
BMI (kg/m2) 26.3 ± 4.1 
Current smoker 32 (6.7%) 
Alcohol consumption (standard units/week)b 1.0 (0.5; 7.0) 
Physical activity (days/month)b 2.0 (0.0; 10.0) 
Erythrocyte folate (µg/L) 344.2 ± 155.3 
MTHFR 677C>T genotype (% CC / CT / TT) 42.4 / 44.3 / 13.2 
MTHFR 1298A>C genotype (% AA / AC / CC) 50.8 / 41.2 / 8.0 
APOE E4 carrier status  126 (26.5%) 
Values represent n (%) or means ± SD. BMI, body mass index; MTHFR, 5,10-
methylenetetrahydrofolate reductase; APOE, apolipoprotein E. 
a Based on Moray House Test No. 12 score, corrected for age at the time of testing. 
b Median value (interquartile range) is given because of skewed data distribution.
